NCT04647461

Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: CHA University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-T Eye drops 0.15% and ALPHAGAN-P Eye drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Detailed description

Following 12 weeks of administration of BRIDIN-T Eye drops 0.15%(non preservative) or ALPHAGAN-P Eye drops 0.15%(preservatives) for patients with glaucoma or Ocular Hypertensive Patients. The use of BRIDIN-T Eye drops(non preservative) is less harmful to external ophthalmicus diseases and increase of medication compliance for ophthalmic drugs than the ALPHAGAN-P Eye drops 0.15%(preservatives)

Conditions

• Glaucoma
• Ocular Hypertensive

Interventions

Type	Name	Description
DRUG	Brimonidine Tartrate 1.5mg	1 drop 3 times a day for 12 weeks to target eyes
DRUG	Brimonidine Tartrate 1.5mg	1 drop 3 times a day for 12 weeks to target eyes

Timeline

• Start date: 2019-03-20
• Primary completion: 2021-01-29
• Completion: 2021-01-29
• First posted: 2020-12-01
• Last updated: 2020-12-01

Locations

1 site across 1 country: South Korea